Anthony Tolcher is CEO and Founder of NEXT Oncology at NEXT Oncology. OpenAlex indexes 991 publications with 24,620 citations (h-index 76); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Anthony Tolcher is CEO and Founder of NEXT Oncology. The public record shows 991 publications with 24,620 citations (h-index 76), centered on Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, PI3K/AKT/mTOR signaling in cancer. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 59 companies, 2 NIH-funded awards (1999–2007).
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Cancer Immunotherapy and Biomarkers
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 59 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 275.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- PTX-35 in Patients With Advanced Solid Tumors
Sponsor: Pelican Therapeutics, Inc.
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
Sponsor: NatureWise Biotech & Medicals Corporation
Industry payments
Updated 18 Oct 2026
59 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20255 payments$16,841openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20251 payment$11,536openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
56.5%RANK Ligand Inhibitor56.5%Denosumab100%Part B, office-administered≥18 patientsBlood & clotting
36.9%Parenteral Iron Replacement36.7%Iron sucrose100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.2%Eliquis65%Xarelto36%Part D<11 patientsSensory organs
3.4%Corticosteroid3.4%Dexamethasone sodium phosphate98%Hydrocortisone3%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
2 NIH research awards on record, funded 1999–2007 per NIH RePORTER. The latest:
- PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL
University of Texas Hlth Science Center
FY2007$12,053M01RR001346 - Phase I Clinical Trials of Anti-Cancer Agents
Cancer Therapy and Research Center
FY2006$497,588U01CA069853 - PH I STUDY OF EGFR AND HER2 BLOCKADE W/ OSI-774, TRASTUZUMAB AND PACLITAXEL
University of Texas Hlth Science Center
FY2006$23,191M01RR001346
Congress activity
Updated 18 Oct 2026
229 congress contributions (2005–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.
Cancer research communications
Clinical Trial2026 - Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
Clinical cancer research
Clinical Trial2026 - Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
Clinical Trial2026 - An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors.
Clinical and translational science
Clinical Trial2026 - A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesArticle2,506 citations2010
- 02
- 03
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/anthony-tolcher-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
texasoncology.com/oncologist/anthony-tolcher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
University of British Columbia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Residency in Internal Medicine
University of Toronto
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasoncology.com ↗ - Fellowship in Oncology
University of British Columbia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Research Fellowship
National Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.navigatingcare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- Diplomate
American Board of Internal Medicine and Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Editorial & leadership roles
journal and society appointments- President and Co-Founder
South Texas Accelerated Research Therapeutics (START LLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Member
American Society of Clinical Oncology Scientific Program Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Member
ASCO Cancer Education Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Chair
Developmental Therapeutics Review Committee for AACO Annual Scientific Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Associate Editor
Journal of New Anticancer Agents
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasoncology.com ↗ - Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Member
American Society of Clinical Oncologists
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasoncology.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasoncology.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center